Four steps for reducing the risks of temperature excursion

By World Courier

In clinical trials, the cold chain is far from a secondary concern. When it comes to temperature-sensitive products (tissue samples, cell banks, APIs), any temperature excursion can prove detrimental to the shipment, and ultimately to the trial. Supply chains are not always predictable or easy to control, and pharma companies need to take a proactive approach to risk management. Sue Lee, technical portfolio manager at World Courier, explains how companies can determine their risks and plan a shipment strategy accordingly.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.